We are engaging a select group of strategic investors and technical advisors to build a pioneering indigenous silk biomaterials company — led by a focused, de-risked bone fixation program.
Silk’s biocompatibility is established by a century of surgical use.
Few advanced regenerated-silk devices exist; fixation is largely open.
India’s silk production base can feed high-value medical devices.
The founder demonstrated the silk-cryogel bone material is feasible — and is an ISO 10993 expert.
Build the advantage in India, serve the patient worldwide. A ~$10B global trauma-fixation market and ~178M fractures a year, addressed from a low-cost, silk-rich base — with little direct competition in bioresorbable silk fixation.
Figures are directional, from widely-published sources. Full TAM / SAM / SOM sizing & competitive analysis are in the confidential brief.
The science is the moat; the model is deliberately conventional — a single-use, premium implant in an established, reimbursable category, with a structural cost advantage from an indigenous raw material.
Each procedure uses the implant once. SilkMatrix sells a high-value, single-use device into an existing surgical workflow — not a one-off sale.
Orthopaedic fixation already has clinical adoption and reimbursement pathways — we innovate the material, not the entire market.
An indigenous, renewable silk base — versus imported alloys and petrochemical polymers — supports attractive margins and import substitution.
Prove the lead device, then scale the platform. A single validated bone-fixation product opens the category; the same material science then extends into scaffolds, wound matrices and beyond — each new line built on shared, already-validated science rather than a fresh start.
India-first, global-ready. Develop and validate in a low-cost, silk-rich base, then pursue CE Mark / FDA pathways for global reach — sequenced behind clinical and regulatory milestones, leveraging the founder’s regulatory expertise.
SilkMatrix’s direction is not a hopeful bet. In his graduate research at IIT Kanpur, the founder demonstrated a silk-fibroin cryogel for bone fixation with compressive strength comparable to human bone and bone-like porosity — proving feasibility with his own hands.
He then became an ISO 10993 biocompatibility expert (EU MDR / FDA / CDSCO) and a Marie Curie implant researcher at INSERM. The two activities that sink most implant ventures — making the material and proving it safe to regulators — are both founder strengths. The venture builds its own, independently-owned IP from this proven foundation.
See the full founder case →Capital is committed against evidence. Each phase concludes with an explicit Go / No-Go decision before the next begins — protecting investor capital and focusing the team.
Prove reproducibility, formulation, early safety, and IP / legal readiness.
Develop the screw / plate system, verify mechanics, and complete biological & animal validation.
The foundation round funds three things: standing up the R&D lab, building a modern, clinical-grade product from proven science, and securing the venture’s own IP. Specific budgets and terms are shared confidentially with qualified investors; publicly, we commit to clear milestones.
This round stands up the venture’s R&D lab, then delivers reproducible formulation, early safety signals, and the venture’s own filed IP — the foundation for product development.
Mechanically verified, ISO 10993 evaluated, and tested in small- and large-animal models.
Readiness for scaled, quality-controlled manufacturing and the regulatory / clinical pathway.
We are at the foundation stage and in early conversations with prospective investors and advisors. This is an opportunity to shape the company from the start.
Straight answers to the most common questions. The full detail — financials, risk register, IP and regulatory strategy — is shared with qualified investors in the confidential brief.
All intellectual property is developed for, and owned entirely by, the company — built on a decade of the founder’s domain expertise. There is no competing institutional claim. The IP strategy and filing plan are detailed in the confidential brief.
Feasibility is already demonstrated: the founder engineered a silk-fibroin cryogel with compressive strength comparable to human bone and bone-like porosity. This round funds turning that proven science into a modern, clinical-grade device under formal design controls.
The foundation round establishes the R&D lab, builds and characterises the device, secures the company’s own IP, and advances biological and preclinical validation. Capital is deployed against milestones with explicit Go / No-Go gates. Budgets and terms are in the brief.
The founder covers the two areas that sink most implant ventures — the silk material science and ISO 10993 / regulatory expertise. The company is structured to surround him with clinical, manufacturing and quality advisors, which are being assembled as the round closes.
The program is designed toward ISO 10993 biological evaluation from day one, with a staged path across CDSCO, EU MDR and FDA. The founder prepares these submissions professionally. The detailed regulatory strategy and timeline are in the confidential brief.
India is one of the world’s largest silk producers yet imports most of its medical devices — a clear raw-material and policy advantage for indigenous implants. Bioresorbable regulatory frameworks are maturing, and silk’s safety is already proven. The pieces are aligning now.
Yes. The founder’s professional profile, peer-reviewed publications and regulatory practice are independently verifiable via LinkedIn, ResearchGate and his consultancy — all linked from the Founder page.
The bone-fixation device is the proof point — not the destination. The same silk material science extends into scaffolds, wound healing, dental, coatings and drug delivery. We are building the company that turns an indigenous, renewable material into a family of regenerative medical devices.
Validate the lead bone-fixation device — the platform’s most demanding test.
Extend into scaffolds and wound healing — reusing already-validated science.
Become a reference name in indigenous silk biomaterials — built on owned IP.
The science is proven; the company is forming. Early capital now shapes a venture with de-risked technology, a regulatory-qualified founder, and 100%-owned IP — before institutional pricing.
Specific amount, valuation and terms are shared with qualified investors under NDA.
Share a few details and we’ll follow up to arrange access to the full technical & investment brief under confidentiality.